D
Danila Covelli
Researcher at University of Milan
Publications - 46
Citations - 1585
Danila Covelli is an academic researcher from University of Milan. The author has contributed to research in topics: Graves' disease & Thyroid. The author has an hindex of 18, co-authored 41 publications receiving 1080 citations. Previous affiliations of Danila Covelli include Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico.
Papers
More filters
Journal ArticleDOI
Efficacy of B-cell Targeted Therapy With Rituximab in Patients With Active Moderate to Severe Graves' Orbitopathy: A Randomized Controlled Study
Mario Salvi,Guia Vannucchi,Nicola Currò,Irene Campi,Danila Covelli,Davide Dazzi,Simona Simonetta,Claudio Guastella,Lorenzo Pignataro,Sabrina Avignone,Paolo Beck-Peccoz +10 more
TL;DR: The better eye motility outcome, visual functioning of the quality of life assessment, and the reduced number of surgical procedures in patients after RTX seem to suggest a disease-modifying effect of the drug.
Journal ArticleDOI
SARS-CoV-2-related atypical thyroiditis.
Ilaria Muller,Ilaria Muller,Daniele Cannavaro,Davide Dazzi,Danila Covelli,Giovanna Mantovani,Antonio Muscatello,Emanuele Ferrante,Emanuela Orsi,Veronica Resi,Virgilio Longari,Marco Cuzzocrea,Alessandra Bandera,Elisa Lazzaroni,Alessia Dolci,Ferruccio Ceriotti,Tiziana E Re,Andrea Gori,Maura Arosio,Mario Salvi +19 more
Journal ArticleDOI
Mycophenolate plus methylprednisolone versus methylprednisolone alone in active, moderate-to-severe Graves' orbitopathy (MINGO): a randomised, observer-masked, multicentre trial.
George J. Kahaly,M. Riedl,Jochem König,Susanne Pitz,Katharina A. Ponto,Tanja Diana,Elena Kampmann,Elisa Kolbe,Anja Eckstein,Lars C. Moeller,Dagmar Führer,Mario Salvi,Nicola Currò,Irene Campi,Danila Covelli,Marenza Leo,Michele Marinò,Francesca Menconi,Claudio Marcocci,Luigi Bartalena,Petros Perros,Wilmar M. Wiersinga +21 more
TL;DR: This trial aimed to compare the efficacy and safety of add-on mycophenolate to methylprednisolone in comparison with methylpredisonsolone alone in patients with moderate-to-severe Graves' orbitopathy.
Journal ArticleDOI
Therapeutic outcomes of high-dose intravenous steroids in the treatment of dysthyroid optic neuropathy.
Nicola Currò,Danila Covelli,Guia Vannucchi,Irene Campi,Giacinta Pirola,Simona Simonetta,Davide Dazzi,Claudio Guastella,Lorenzo Pignataro,Paolo Beck-Peccoz,Roberto Ratiglia,Mario Salvi +11 more
TL;DR: High-dose iv-MP was effective in permanently restoring visual function in about 40% of the eyes treated, and the presence of optic disc swelling at diagnosis and persistent active disease at two weeks were good predictors of unresponsiveness to steroids.
Journal ArticleDOI
Small dose of rituximab for graves orbitopathy: New insights into the mechanism of action
Mario Salvi,Guia Vannucchi,Nicola Currò,Martino Introna,Stefania Rossi,Paola Bonara,Danila Covelli,Davide Dazzi,Claudio Guastella,Lorenzo Pignataro,Roberto Ratiglia,Josée Golay,Paolo Beck-Peccoz +12 more
TL;DR: Bupropion is a common medication, and it is unclear why other cases have not been reported; the absence of other similar reports may reflect underreporting; alternatively, this patient may harbor a rare, private polymorphism that causes bupropion or one of its metabolites to become a particularly potent choroidal vasodilator.